The longevity evidence standard

Across every mechanism in this network, there is no human lifespan RCT. Not one of the sites mapped here has a randomized controlled trial with a healthy-aging lifespan endpoint. What each site holds is weaker, honestly graded evidence — animal-lifespan data, human biomarker trials, small pilots, or disease-population outcomes. This hub is a map of graded evidence, not advice: it never stacks interventions, never gives a dose, and never tells you to combine sites into a plan.

Why we state this once, here

Every mechanism site in this network carries its own honest flags. Rather than repeat the framing on each site, the network states its standard in one canonical place — this page — that every site links back to. The standard is simple: we grade evidence on a visible scale and we never collapse it into a single marketing score, and we report what studies measured rather than recommend what you should do.

The central fact

No mechanism in this network has a healthy-aging human lifespan randomized controlled trial. Tier 1 is empty everywhere. That is not an oversight in our sourcing; it is the state of the field. Human data does exist — biomarker RCTs, small pilots, and hard clinical outcomes in disease populations — but a biomarker change or a disease-population result is not evidence that an intervention extends healthy human lifespan.

The shared evidence-tier scale

The canonical scale lives on the methodology page and is reproduced there in full. In short: tier 1 is a healthy-aging lifespan RCT (empty network-wide); tiers 2–4 are the human evidence that does exist (disease-outcome RCT, biomarker RCT, pilot/observational); tiers 5–7 are animal and mechanism data.

Report, don’t recommend

The network reports findings; it does not prescribe. It publishes no dose, no cycling schedule, no protocol, and no calculator. It never aggregates across sites into a plan: visiting more than one site does not yield a stack or a regimen, and the hub will never tell you to combine interventions. Where an outcome was measured in a disease population, that context is stated plainly and is never presented as a healthy-aging benefit.